Director, Regulatory Affairs (Global Filing Lead) Revolution MedicinesDirector, Regulatory Affairs (Global Filing Lead)Redwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Director, GLP Quality Assurance Revolution MedicinesDirector, GLP Quality AssuranceRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Director, Good Laboratory Practice Quality Assurance (GLP QA) is responsible for ensuring Good Laboratory Practices (GLP) compliance at RevMed and external vendors contracted to perform regulated work on behalf of RevMed including all GLP vendors.
Associate Director, Global Omnichannel Solutions Delivery Revolution MedicinesAssociate Director, Global Omnichannel Solutions DeliveryRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The individual will play a critical role in supporting global expansion by establishing scalable solutions, enabling adoption of global platforms, and ensuring new capabilities, brands, and regions can be added efficiently without rework or fragmentation.
Director, Stability Management, Analytical Development and Quality Control Revolution MedicinesDirector, Stability Management, Analytical Development and Quality ControlRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Collaborate cross-functionally with teams in drug substance, drug product, supply chain, quality, regulatory, sourcing and other related team to ensure alignment of stability design and achieve stability study objectives.
Senior Director, Global Value Access and Pricing, NSCLC Revolution MedicinesSenior Director, Global Value Access and Pricing, NSCLCRedwood City, CaliforniaRemoteThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As the Global Value & Access lead on Disease Area Strategy Teams and governance forums, the Senior Director influences clinical development, indication sequencing, lifecycle management, launch planning, and business development decisions to maximize long-term asset value and sustainable patient access.
Director, Molecular Pathology, Translational Sciences, Translational Research. Revolution MedicinesDirector, Molecular Pathology, Translational Sciences, Translational Research.Redwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a Director, Molecular Pathology, you will be a key member of a cross-functional Translational Sciences Team, reporting to the Senior Director and Head of Translational Sciences within Translational Research and will: Biomarker Strategy: Define and execute molecular and digital pathology-driven biomarker strategies.
Associate Director, Biostatistics Clinical Late Stage Revolution MedicinesAssociate Director, Biostatistics Clinical Late StageRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Executive Director, Computational Systems Biology Revolution MedicinesExecutive Director, Computational Systems BiologyRedwood City, CaliforniaThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Senior Director, Molecule Global Regulatory Lead Revolution MedicinesSenior Director, Molecule Global Regulatory LeadRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provide strategic oversight for the planning and execution of major regulatory submissions, including INDs, CTAs, amendments, expedited designation requests, marketing applications, and lifecycle submissions.
Oversight Director, Clinical Operations Maze TherapeuticsOversight Director, Clinical OperationsSouth San Francisco, CA$232,000–$283,000 / yearCross-functional Collaboration Collaborate closely with Clinical Science, Regulatory Affairs, Data Science, Pharmacovigilance, Biometrics, Medical Monitoring, Clinical Supply, CMC, Tech Ops, Finance, and other cross-functional partners to influence asset strategy and drive successful program execution. Clinical Development & Portfolio Collaboration Provide strategic and operational direction across an assigned development asset spanning CKD and PKU clinical programs, ensuring alignment between clinical development strategy and operational execution from protocol development through study closeout and regulatory readiness.
Associate Director, Product Design-Mobile AbbottAssociate Director, Product Design-MobileAlameda, California$148,700–$297,300 / yearCollaborate Cross-Functionally : Partner closely with product management, engineering, brand, and marketing to deliver cohesive, high-impact experiences across mobile and web platforms. This role is ideal for a strategic design leader who thrives in fast-paced environments, is deeply passionate about user-centered design, and is excited to shape the future of health technology at scale.
Director, Regulatory Affairs (US Filing Lead) Revolution MedicinesDirector, Regulatory Affairs (US Filing Lead)Redwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Director Machine Learning, Drug Discovery Analytics Revolution MedicinesDirector Machine Learning, Drug Discovery AnalyticsRedwood City, CaliforniaThe successful candidate will play a key role in advancing a data-driven discovery strategy by designing predictive models, deploying innovative algorithms, and translating insights into actionable decisions that improve the speed and success of the discovery of medicines for patients with RAS-driven cancers. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Clinical Operations Compliance & Training Revolution MedicinesAssociate Director, Clinical Operations Compliance & TrainingRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.
Director, US Analytics, Lung Revolution MedicinesDirector, US Analytics, LungRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. This role will partner closely with Commercial, Medical Affairs, Market Access, Clinical Development, and Business Operations to generate actionable insights that inform portfolio strategy, launch readiness, commercialization planning, and business performance.
Regional Insights and Engagement Director, Lung, Central Rockies Revolution MedicinesRegional Insights and Engagement Director, Lung, Central RockiesRedwood City, CaliforniaRemoteThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner with Sales, Medical Affairs, Market Access, and Commercial Operations & Business Analytics teams to ensure alignment of RevMed’s US commercialization strategy; Uncovers, prioritizes, and communicates market insights, challenges/barriers, and solutions to the organization.
Associate Director, Business Operations Revolution MedicinesAssociate Director, Business OperationsRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The role is ideal for a Associate Director –level professional who thrives on execution, can drive several projects in parallel, can navigate a matrix environment, and brings strong project leadership, communication and change management experience.
Associate Director, Clinical Data Management Revolution MedicinesAssociate Director, Clinical Data ManagementRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Senior Program Director (Commercial Regulatory Affairs, Fully Remote) Dawar ConsultingSenior Program Director (Commercial Regulatory Affairs, Fully Remote)South San Francisco, CaliforniaRemoteYou will lead Promotional Review Committees (PRCs), review and approve advertising and promotional materials, and partner closely with Marketing, Medical Affairs, Legal, and Compliance to ensure FDA‑compliant communications. Our client, a world leader in biotechnology and life sciences, is seeking a " Senior Program Director, Commercial Regulatory Affairs ".
Executive Director, Clinical Supply Chain Revolution MedicinesExecutive Director, Clinical Supply ChainRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.